Skip to Content
Merck
CN

P0080

Pranlukast hemihydrate

≥98% (HPLC), CysLT1 receptor antagonist, solid

Synonym(s):

8-[4(4-phenylbutoxy)benzoyl]amino-2-(5-tetrazolyl)-4-oxo-4H-1-benzopyran

Sign In to View Organizational & Contract Pricing.

Select a Size


About This Item

Empirical Formula (Hill Notation):
C27H23N5O4 · 0.5 H2O
CAS Number:
Molecular Weight:
490.51
UNSPSC Code:
51111800
PubChem Substance ID:
NACRES:
NA.77
MDL number:
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Pranlukast hemihydrate, ≥98% (HPLC), white, solid

SMILES string

O.O=C(Nc1cccc2C(=O)C=C(Oc12)c3nnn[nH]3)c4ccc(OCCCCc5ccccc5)cc4.O=C(Nc6cccc7C(=O)C=C(Oc67)c8nnn[nH]8)c9ccc(OCCCCc%10ccccc%10)cc9

InChI key

MSXTUBJFNBZPGC-UHFFFAOYSA-N

InChI

1S/2C27H23N5O4.H2O/c2*33-23-17-24(26-29-31-32-30-26)36-25-21(23)10-6-11-22(25)28-27(34)19-12-14-20(15-13-19)35-16-5-4-9-18-7-2-1-3-8-18;/h2*1-3,6-8,10-15,17H,4-5,9,16H2,(H,28,34)(H,29,30,31,32);1H2

assay

≥98% (HPLC)

form

solid

color

white

solubility

DMSO: ≥10 mg/mL
H2O: insoluble

storage temp.

−20°C

Quality Level

Related Categories

Biochem/physiol Actions

Pranlukast is a subtype specific CysLT1 receptor antagonist.
Pranlukast is a subtype specific CysLT1 receptor antagonist. Leukotrienes are involved in the inflammation response and are divided into two main classes; leukotriene B4 and cysteinyl-substituted leukotrienes.

Features and Benefits

This compound is featured on the Leukotriene Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

pictograms

Exclamation mark

signalword

Warning

Hazard Classifications

Acute Tox. 4 Oral - Aquatic Chronic 4 - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

target_organs

Respiratory system

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Inés Velázquez-Quesada et al.
Drug design, development and therapy, 14, 1799-1811 (2020-06-05)
Cancer stem cells (CSCs) drive the initiation, maintenance, and therapy response of breast tumors. CD49f is expressed in breast CSCs and functions in the maintenance of stemness. Thus, blockade of CD49f is a potential therapeutic approach for targeting breast CSCs.
Eun-Sol Ha et al.
Drug design, development and therapy, 9, 3257-3266 (2015-07-08)
The present study was carried out to develop an oral formulation of pranlukast hemihydrate with improved dissolution and oral bioavailability using a surface-modified microparticle. Based on solubility measurements, surface-modified pranlukast hemihydrate microparticles were manufactured using the spray-drying method with hydroxypropylmethyl

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service